Who provided the loan?

Upsher-Smith Laboratories, LLC, a 100% indirect subsidiary of Borun, provided the loan.

What is the purpose of the funds?

To finance U.S. drug regulatory approval and related rights acquisition.

Loan amount and interest rate?

NT$798 million at 5.2% annual interest, repayable within one year.

No collateral provided; borrower has strong retained earnings but minimal capital.

Why is this loan significant?

It advances Borun's U.S. market strategy and supports future revenue growth.

AI News NQ Analysis

[Borun] Announcement and Filing by Important Subsidiary Upsher-Smith Laboratories, LLC Pursuant to Article 22, Paragraph 1, Clause 3 of the 'Guidelines for Loans and Guarantees by Publicly Issued Companies'

NQ Score 77/100

N1 Content Completeness 9

AI Summary (NQ-processed)

Upsher-Smith Laboratories, LLC, a 100% indirectly held subsidiary of Borun, has extended an unsecured loan of NT$798 million to Bora Pharmaceutical Holdings, LLC. The funds will be used as working capital to obtain U.S. drug approvals and related rights. The annual interest rate is 5.2%, with repayment due in full within one year.

AI Analysis

Frequently Asked Questions

Q: Who provided the loan?: A: Upsher-Smith Laboratories, LLC, a 100% indirect subsidiary of Borun, provided the loan.
Q: What is the purpose of the funds?: A: To finance U.S. drug regulatory approval and related rights acquisition.
Q: Loan amount and interest rate?: A: NT$798 million at 5.2% annual interest, repayable within one year.
Q: Is there collateral?: A: No collateral provided; borrower has strong retained earnings but minimal capital.
Q: Why is this loan significant?: A: It advances Borun's U.S. market strategy and supports future revenue growth.